Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04872348 · ClinicalTrials.gov registry record
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
A clinical trial, sponsored by Sight Sciences.
- Completed
- Registry status
- 28
- Enrollment target
NCT04872348: Completed study, sponsored by Sight Sciences.
NCT04872348 is a clinical trial that has completed, run by Sight Sciences. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04872348 has completed, sponsored by Sight Sciences.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in pseudophakic eyes with mild to moderate primary open angle glaucoma (POAG) at least 150 days prior to enrollment.
Primary Outcome
Percent change in unmedicated diurnal intraocular pressure (DIOP/washout) or medicated intraocular pressure (IOP/no washout) compared to baseline.
Interventions
- DEVICE OMNI® Surgical System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2023-11-02 |
What the finished NCT04872348 record still lists
NCT04872348 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which OMNI® Surgical System is the first listed.
NCT04872348 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04872348 about?
NCT04872348 is a clinical study titled "An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)". The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in pseudophakic eyes with mild to moderate primary open angle glaucoma (POAG) a...
What is the current status of trial NCT04872348?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2021-07-01. Estimated completion is 2023-11-02.
What interventions are being tested in trial NCT04872348?
The interventions under investigation include: OMNI® Surgical System (DEVICE).
Who is sponsoring clinical trial NCT04872348?
This trial is sponsored by Sight Sciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI